

Supplementary Information

Ferulic and *p*-Coumaric Acid Derivatives as Dual EGFR-VEGFR2 Inhibitors: Design, Semi-Synthesis and Biological Investigations

Ranza Elrayess ^{a, b*†}, Mohamed S. Nafie ^{c, d†}, Safwat A. Ahmed ^e, Yosra K. Alkazzaz ^f, Khaled M. Darwish ^{g, h}, Heba N. Gad EL-Hak ⁱ, Enas E. Eltamany ^{e*}.

^a *Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Suez Canal University, Ismailia 41522, Egypt*

^b *Pharmaceutical Organic Chemistry Department, College of Pharmacy, Al-Ayen Iraqi University, An Nasiriyah, 64001, Iraq*

^c *Department of Chemistry, College of Sciences, University of Sharjah, Sharjah, 27272, United Arab Emirates.*

^d *Department of Chemistry, Faculty of Science, Suez Canal University, Ismailia 41522, Egypt*

^e *Pharmacognosy Department, Faculty of Pharmacy, Suez Canal University, Ismailia 41522, Egypt*

^f *Institute of Biotechnology for Postgraduate Studies and Research, Suez Canal University, Ismailia, 41522, Egypt*

^g *Department of Medicinal Chemistry, Faculty of Pharmacy, Suez Canal University, Ismailia, Egypt*

^h *Department of Medicinal Chemistry, Faculty of Pharmacy, Galala University, New Galala 43713, Egypt.*

ⁱ *Department of Zoology, Faculty of Science, Suez Canal University, Ismailia 41522, Egypt*

† Ranza Elrayess and Mohamed S. Nafie contributed equally to this study

*Corresponding authors:

Ranza Elrayess: Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Suez Canal University, Ismailia 41522, Egypt; Email: Ranza.el-rayes@pharm.suez.edu.eg

Enas E. Eltamany: Pharmacognosy Department, Faculty of science, Suez Canal University, Ismailia 41522, Egypt; Email: enas_mostafa@pharm.suez.edu.eg

Supplementary Information

Table of contents

Title	Page
Material and methods, chemistry	3-5
Instrument and reagent used	3
Synthetic procedure of compounds 1 a-b	4
Synthetic procedure of compounds 2 a-b and 3a-h	5
Material and methods, <i>In vivo</i> studies	6-7
Animals and tumor cell lines	6
Antitumor potentiality	6
Histological examinations	7
Immunohistochemical preparation	7
References	7
¹H NMR and ¹³C NMR spectral data of the synthesized compounds 1a-b, 2a-b and 3a-h	8-27
Fig. S1. ¹H-NMR of compound 1a	8
Fig. S2. ¹H-NMR of compound 1b	9
Fig. S3. ¹H-NMR of compound 2a	10
Fig. S4. ¹H-NMR of compound 2b	11
Fig. S5. ¹H-NMR of compound 3a	12
Fig. S6. ¹³C-NMR of compound 3a	13
Fig. S7. ¹H-NMR of compound 3b	14
Fig. S8. ¹³C-NMR of compound 3b	15
Fig. S9. ¹H-NMR of compound 3c	16
Fig. S10. ¹³C-NMR of compound 3c	17
Fig. S11. ¹H-NMR of compound 3d	18
Fig. S12. ¹³C-NMR of compound 3d	19
Fig. S13. ¹H-NMR of compound 3e	20
Fig. S14. ¹³C-NMR of compound 3e	21
Fig. S15. ¹H-NMR of compound 3f	22

Supplementary Information

Fig. S16. ^{13}C -NMR of compound 3f	23
Fig. S17. ^1H -NMR of compound 3g	24
Fig. S18. ^{13}C -NMR of compound 3g	25
Fig. S19. ^1H -NMR of compound 3h	26
Fig. S20. ^{13}C -NMR of compound 3h	27
Fig.S21 Elemental analysis of compounds 1a-b, 2a-b and 3a-h	28
Mass spectral data of the compounds 1a-b, 2a-b and 3a-h	29-39
Fig. S22. Mass spectrum of compound 1a	29
Fig. S23. Mass spectrum of compound 1b	30
Fig. S24. Mass spectrum of compound 2a	31
Fig. S25. Mass spectrum of compound 2b	32
Fig. S26. Mass spectrum of compound 3a	33
Fig. S27. Mass spectrum of compound 3b	34
Fig. S28. Mass spectrum of compound 3c	35
Fig. S29. Mass spectrum of compound 3d	36
Fig. S30. Mass spectrum of compound 3e	37
Fig. S31. Mass spectrum of compound 3f	38
Fig. S32. Mass spectrum of compound 3h	39
Fig. S33. IC_{50} curves (for MCF-7, HepG2 and A594) of the compounds 2a-b & 3a-h	40-41

3. Material and methods

3.1 chemistry

3.1.1. Instrument

On a Stuart melting point apparatus (SMP10), the uncorrected melting points of all materials were measured. On Pye-Unicam SP-3-300 infrared spectrophotometer (KBr disks), the IR spectra were captured and expressed in wave number (cm^{-1}). On a Bruker Avance III NMR spectrometer, 400 MHz, ^1H -NMR spectra were run. At the School of Pharmacy, Ain Shams University, the ^{13}C -NMR spectra (δ , ppm) were conducted at 100 MHz and 125 MHz on a BRUKER NMR spectrometer (BRUKER, Manufacturing & Engineering Inc., Anaheim, CA, USA). TMS was utilized in deuterated dimethyl sulfoxide as an internal standard (DMSO- d_6). Ppm is used to quote

Supplementary Information

chemical shifts (δ). These acronyms are used: s for singlet; d for doublet; and m for multiplet. All values for the coupling constant (J) are given in hertz. On a Shimadzu GCMSQP-1000EX mass spectrometer, the mass spectra were captured at a 70 eV energy level. The reactions were monitored by thin-layer chromatography (TLC) using TLC sheets coated with UV fluorescent silica gel Merck 60 F254 plates and were visualized using a UV lamp and different solvents as the mobile phase.

3.1.2. Chemical and reagents

p-Coumaric acid, ferulic acid, ethyl-2-chloroacetate, hydrazine hydrate, benzaldehyde, *m*-nitro benzaldehyde, anisaldehyde and 3,4,5 trimethoxy benzaldehyde were purchased from Aldrich (USA). Solvents and other reagents were of pure grade and used without further purification.

2-Ethoxy-2-oxoethyl (*E*)-3-(4-(2-ethoxy-2-oxoethoxy)-3-substituted phenyl) acrylate (1a-b)

p-Coumaric acid/ ferulic acid (0.1 mol) was dissolved in *N,N*-dimethylformamide (DMF 100 ml) and mixed with anhydrous potassium carbonate (0.16 mol). Ethyl 2-chloroacetate (0.1 mol) was added, and the mixture refluxed for 12 h. The reaction mixture was cooled and poured into crushed ice. The crude product was filtered and recrystallized from ethanol ¹.

2-Ethoxy-2-oxoethyl (*E*)-3-(4-(2-ethoxy-2-oxoethoxy)phenyl)acrylate (1a)

White; Yield 81 %; M.p.; 118-120 °C; IR (cm⁻¹):1690(C=O),1248(C-O-C). EI-MS (m/z, %): 336 (M⁺); ¹H NMR (400 MHz, DMSO-d₆): δ 7.72 (d, J = 8 Hz, 2H, Ar-H), 7.69 (d, J = 16 Hz, 1H, CH=CH), 6.99 (d, J = 8 Hz, 2H, Ar-H), 6.60 (d, J = 16 Hz, 1H, CH=CH), 4.86 (s, 2H, O-CH₂), 4.76 (s, 2H, COO-CH₂), 4.18 (q, J = 12 Hz, 4H, 2xCH₂ CH₃), 1.22 (t, J = 8 Hz, 6H, 2xCH₂-CH₃). Anal.Calc'd. for C₁₇H₂₀O₇: C, 60.71; H, 5.99; O, 33.30. Found: C,60.94 ; H,6.08.

2-Ethoxy-2-oxoethyl(*E*)-3-(4-(2-ethoxy-2-oxoethoxy)-3 methoxyphenyl)acrylate (1b)

White; Yield 81 %; M.p.; 88-90 °C; IR (cm⁻¹):1614(C=O),1275(C-O-C) EI-MS (m/z, %): 366 (M⁺); ¹H NMR (400 MHz, DMSO-d₆): δ 7.67 (d, J = 16 Hz, 1H, CH=CH), 7.46 (s, 1H, Ar-H), 7.26 (d, J = 8 Hz, 1H, Ar-H), 6.91 (d, J = 8 Hz, 1H, Ar-H), 6.68 (d, J = 16 Hz, 1H, CH=CH), 4.84 (s, 2H, O-CH₂), 4.77 (s, 2H, COO-CH₂), 4.21-4.14 (m, 4H, 2xCH₂ CH₃), 3.85

Supplementary Information

(s, 3H, OCH₃), 1.22 (t, J = 16 Hz, 6H, 2xCH₂-CH₃). Anal. Calcd. for C₁₈H₂₂O₈: C, 59.01; H, 6.05; O, 34.94. Found: C, 59.23; H, 6.18.

2-Hydrazinyl-2-oxoethyl (*E*)-3-(4-(2-hydrazinyl-2-oxoethoxy)-3-substituted phenyl)acrylate (2a-b)

A mixture of compound **1a-b** (0.01 mol) and hydrazine hydrate (0.02 mol) in methanol was refluxed in a water bath for 9 h. After cooling the separated solid was washed with water and dried to give a crude product which were obtained after recrystallization from ethanol².

2-Hydrazinyl-2-oxoethyl(*E*)-3-(4-(2-hydrazinyl-2-oxoethoxy)phenyl)acrylate (2a)

White; Yield 89 %; M.p.: 176-178 °C; IR (cm⁻¹): 3451-3429 (NH₂), 3296 (NH), 1615(C=O), 1259(C-O-C) EI-MS (m/z, %): 308 (M⁺); ¹H NMR (400 MHz, DMSO-d₆): δ 9.38 (s, 2H, 2xNH), 7.68 (d, J = 8 Hz, 2H, Ar-H), 7.62 (d, J = 16 Hz, 1H, CH=CH), 7.00 (d, J = 8 Hz, 2H, Ar-H), 6.51 (d, J = 16 Hz, 1H, CH=CH), 4.55 (s, 2H, COO-CH₂), 4.35 (s, 4H, 2xNH₂), 3.72 (s, 2H, O-CH₂). Anal. Calcd. for C₁₃H₁₆N₄O₅: C, 50.65; H, 5.23; N, 18.17; O, 25.95. Found: C, 50.83; H, 5.44; N, 18.40 .

2-Hydrazinyl-2-oxoethyl(*E*)-3-(4-(2-hydrazinyl-2-oxoethoxy)-3-methoxyphenyl) acrylate (2b)

Pale yellow; Yield 91 %; M.p.: 145-147 °C; IR (cm⁻¹): 3201-3067 (NH₂), 2970(NH), 1657(C=O), 1264 (C-O-C). EI-MS (m/z, %): 338 (M⁺); ¹H NMR (400 MHz, DMSO-d₆): δ 9.20 (s, 2H, 2xNH), 7.60 (d, J = 16 Hz, 1H, CH=CH), 7.39 (s, 1H, Ar-H), 7.23 (d, J = 8 Hz, 1H, Ar-H), 6.93 (d, J = 8 Hz, 1H, Ar-H), 6.59 (d, J = 16 Hz, 1H, CH=CH), 4.52 (s, 2H, COO-CH₂), 4.34 (s, 4H, 2xNH₂), 3.84 (s, 3H, OCH₃), 3.72 (s, 2H, O-CH₂). Anal. Calcd. for: C₁₄H₁₈N₄O₆: C, 49.70; H, 5.36; N, 16.56; O, 28.37. Found: C, 49.94; H, 5.48; N, 16.73 .

General procedure for the synthesis of target compounds (3a-h)

A mixture of compound **2a-b** (0.01 mol) and appropriate aromatic aldehyde (0.01 mol) in the presence of trace amount of glacial acetic acid was refluxed for 5 h. (monitored by TLC) in methanol (20 mL). The solvent was removed under reduced pressure and the product was recrystallized from chloroform³.

Supplementary Information

3.2.4 *In vivo* studies

3.2.4.1 Animals and tumor cell lines

Adult female Swiss albino mice purchased from Theodor Bilharzia Research Institute, Giza, Egypt, with an average body weight of (18-23) g were used. Mice were housed under constant conditions of 12 h light/dark cycle in a temperature-controlled environment under conditions of controlled humidity (22 ± 2 °C), with free access to standard laboratory mice food and water.

Solid Ehrlich carcinoma (SEC) cells were obtained from the National Cancer Institute (Cairo University, Egypt). The tumor cell line was proliferated in mice through serial intraperitoneal (I.P.) transplantation of a volume of 0.2 mL physiological saline containing 1×10^6 viable cells for 24 h. SEC cells were collected 7 days after I.P. implantation. The harvested cells were diluted with saline to obtain a concentration of 5×10^6 viable SEC cells/mL. A volume of 0.2 mL saline contains 1×10^6 SEC cells that were I.P. implanted into each normal mouse. SEC cells (1×10^6 tumor cells/mouse) were implanted subcutaneously into the right thigh of the hind limb.

The experimental animals were randomly divided into four groups. Group 1 served as the normal saline control. Group 2 served as the SEC control (1×10^6 cells/mouse). Group 3 served as the compound **3f**-treated group (6 mg/kg B.Wt., I.P.). Group 4 received the standard anti-cancer drug of Sorafenib (6 mg/kg BW, I.P.) and is considered the reference control. Body weight and survival were recorded daily until the 24th day in both treated and control groups. At the end of the experiment, the anesthetized animals were then sacrificed for the examination of the antitumor activity examination.

3.2.4.2. Antitumor potentiality

It includes tumor volume, weight, and tumor inhibition ratio (TIR%). Time interval measurements of tumor volume using a digital Vernier caliper (Tricle Brand, Shanghai, China). Measure tumor length and width using clipper and then calculate tumor volume using formulations $V = (L \times W \times W)/2$, where V is tumor volume, W is tumor width, L is tumor length. While TIR% was calculated

according to the following equation
$$\frac{\text{Tumor volume (Control)} - \text{Tumor volume (treated)}}{\text{Tumor volume (control)}} \times 100$$

Supplementary Information

3.2.4.3. Histological examinations

Solid ascites tissue samples are usually collected and fixed in neutral formalin. After fixation, the specimens undergo dehydration and clearing processes. The tissues are then embedded in paraffin wax to provide support for sectioning into thin slices of approximately 4-5 micrometers. These sections are stained with Hematoxylin and Eosin (H&E) to assess general tissue structure. The slides are then examined blindly under a light microscope to evaluate histopathological features and associated pathological changes according to Frajacomo, de Souza Padilha.

3.2.4.4. Immunohistochemical preparation

Sections (4 μm) were deparaffinized, rehydrated, and endogenous peroxidase activity was quenched using 3% hydrogen peroxide. Heat-induced epitope retrieval was performed in either citrate buffer (pH 6.0) or Tris-EDTA (pH 9.0) for 20 min at 95–100 °C, depending on the target antigen. After cooling and PBS washing, nonspecific binding was blocked with a commercial protein blocking solution. Sections were incubated with anti-BCL-2 (clone 124, 1:100, CST), anti-cleaved caspase-3 (Asp175, 1:100, CST), and anti-EGFR (clone 31G7, 1:50, Thermo Fisher). Detection was achieved with a polymer-based HRP/DAB system (Dako EnVision™ K5007) and hematoxylin counterstaining. Stained slides were examined under light microscopy, and five representative high-power fields ($\times 400$) per case were analyzed. For objective quantification, digital images were processed in ImageJ. Values from five fields per case were averaged for analysis.

References

- 1 N. Manju, B. Kalluraya, K. Byrappa, M. Abdoh, *IUCrData* **2016**, *1*, 10.1107/S2414314616015947.
- 2 S. Kumar, P. Kumar, N. Sati, *Journal of Pharmacy & Bioallied Sciences* **2012**, *4*, 246.
- 3 R. Elrayess, N. Ghareb, M. Azab, M. Said, *Life Science Journal* **2020**, *10*, 1784-1793.

Supplementary Information




Fig. S1. ¹H-NMR of compound 1a

Supplementary Information

Sep13-2022-abeer.40.fid
YOSRA-RET
PROTON_BSU DMSO {C:\data} abeer 20




Fig. S2. ¹H-NMR of compound 1b

Supplementary Information

Sep13-2022-abeer.50.fid
YOSRA-RCH
PROTON_BSU DMSO (C:\data) abeer 21




Fig. S3. ¹H-NMR of compound 2a

Supplementary Information

Sep13-2022-abeer.70.fid
YOSRA-RNH2
PROTON_BSU DMSO {C:\data} abeer 23




Fig. S4. $^1\text{H-NMR}$ of compound 2b

Supplementary Information




Fig. S5. $^1\text{H-NMR}$ of compound 3a

Supplementary Information




Fig. S6. ^{13}C -NMR of compound 3a

Supplementary Information

Sep13-2022-aber.10.fid
YOSRA-RCM
PROTON_BSU DMSO {C:\data} aber 17




Fig. S7. ¹H-NMR of compound 3b

Supplementary Information




Fig. S8. ^{13}C -NMR of compound **3b**

Supplementary Information




Fig. S9. $^1\text{H-NMR}$ of compound 3c

Supplementary Information




Fig. S10. ^{13}C -NMR of compound **3c**

Supplementary Information




Fig. S11. $^1\text{H-NMR}$ of compound 3d

Supplementary Information




Fig. S12. ^{13}C -NMR of compound 3d

Supplementary Information




Fig. S13. ¹H-NMR of compound 3e

Supplementary Information




Fig. S14. ^{13}C -NMR of compound **3e**

Supplementary Information

Aug10-2022-abeer.60.fid
YOSRA KH-Y
PROTON_BSU DMSO (C:\data) abeer 11




Fig. S15. ¹H-NMR of compound 3f

Supplementary Information




Fig. S16. ^{13}C -NMR of compound **3f**

Supplementary Information

Sep13-2022-aber.20.fid
YOSRA-R30C
PROTON_BSU DMSO (C:\data\ aber 18




Fig. S17. ¹H-NMR of compound 3g

Supplementary Information




Fig. S18. ^{13}C -NMR of compound 3g

Supplementary Information




Fig. S19. ¹H-NMR of compound 3h

Supplementary Information

Aug04-2024-Dr.Dina.60.fid
YOSRAAZAZ-F.3--4.5
C13CPD DMSO {C:\data} Dr.Dina 17





Fig. S20. ^{13}C -NMR of compound 3h

Supplementary Information

Sample code	C-B	C-EST	C-H	C-NO₂	C-OCH₃	C-3,4,5-OCH₃	F-B	F-EST	F-H	F-NO₂	F-OCH₃	F-3,4,5-OCH₃
Paper code	3a	1a	2a	3b	3c	3d	3e	1b	2b	3f	3g	h



جامعة الأزهر
Al-Azhar University
المركز الإقليمي للفطريات وتطبيقاتها
The Regional Center for Mycology and Biotechnology

Requester Data:

Name: Dr. Yousra Khaled Hasanin Fadel
Authority: Faculty of Pharmacy, Suez Canal University

Sample Data:
 Twelve samples had been submitted for elemental analysis.

Analysis Report:

Sample Code	C%	H%	N%
C-B	67.19	5.07	11.78
C-EST	60.94	6.08	0
C-H	50.83	5.44	18.40
C-NO ₂	64.15	5.29	10.45
C-OCH ₃	56.71	3.98	14.89
C-3,4,5-OCH ₃	59.80	5.67	8.69
F-B	49.94	5.48	16.73
F-EST	59.23	6.18	0
F-H	65.62	5.19	11.06
F-NO ₂	55.49	4.13	14.15
F-OCH ₃	62.88	5.41	9.94
F-3,4,5-OCH ₃	59.05	5.67	8.26


INVESTIGATOR

Dr. y.s. m. fadel

DIRECTOR

M. Mansour

17.7.2024



شارع المسليم الدائم - مدينة نصر - القاهرة
 البريد الإلكتروني: remb@azhar.edu.eg
 الموقع الإلكتروني:
 هاتف: ١٧٤١ مدينة نصر للقاهرة


تلفون: ٢٢٢٢.٢٧٢ (٠٢٠٢) فاكس: ٢٢٢٢.٢٧٢ (٠٢٠٢)
<http://www.azhar.edu.eg.htm>
http://www.azhar.edu.eg/pages/fungi_center.htm
 Facebook: RCMB AZHAR

Figure S21. Elemental analysis of synthesized compounds 1a-b, 2a-b and 3a-h


Supplementary Information

Figure S22. Mass spectrum of compound 1a

RT: 1.75 - 1.97 SM: 7B




CEST #167 RT: 2.81 P: + NL: 3.07E2
T: {0,0} + c EI Full ms [40.00-1000.00]




Supplementary Information

Figure S23. Mass spectrum of compound 1b




F-EST #304 RT: 5.10 P: + SB: 25 3.93-4.03, 3.88-4.17 NL: 1.11E3
T: {0,0} + c EI Full ms [40.00-1000.00]




Supplementary Information

Figure S24. Mass spectrum of compound 2a

RT: 3.04 - 3.60 SM: 7B




CH #89 RT: 1.51 P: + NL: 3.96E2
T: {0,0} + c EI Full ms [40.00-1000.00]




Supplementary Information

Figure S25. Mass spectrum of compound 2b




FH #141 RT: 2.38 P: + SB: 2 1.07, 1.21 NL: 1.81E3
T: {0,0} + c EI Full ms [40.00-1000.00]




Supplementary Information

Figure S26. Mass spectrum of compound 3a




CB #157 RT: 2.64 P: + NL: 7.34E2
T: {0,0} + c EI Full ms [40.00-1000.00]




Supplementary Information

Figure S27. Mass spectrum of compound 3b

RT: 0.87 - 1.22 SM: 7B




CNO2 #72 RT: 1.22 P: + NL: 3.15E2
T: {0,0} + c EI Full ms [40.00-1000.00]




Supplementary Information

Figure S28. Mass spectrum of compound 3c

RT: 0.95 - 3.20 SM: 7B




COCH3 #304 RT: 5.10 P: + SB: 18 4.17, 4.25-4.52 NL: 1.66E3
T: {0,0} + c EI Full ms [40.00-1000.00]




Supplementary Information

Figure S29. Mass spectrum of compound 3d




C-345-OCH3 #278 RT: 4.67 P: + SB: 2 5.09, 5.10 NL: 3.78E3
T: {0,0} + c EI Full ms [40.00-1000.00]




Supplementary Information

Figure S30. Mass spectrum of compound 3e

RT: 2.25 - 3.52 SM: 7B




FB #100 RT: 1.69 P: + SB: 22 1.02-1.17, 0.94-1.12 NL: 1.21E3
T: {0,0} + c EI Full ms [40.00-1000.00]




Supplementary Information

Figure S31. Mass spectrum of compound 3f

RT: 2.05 - 2.53 SM: 7B




FNO2 #255 RT: 4.28 P: + SB: 2 4.28, 4.27 NL: 6.45E2
T: {0,0} + c EI Full ms [40.00-1000.00]




Supplementary Information

Figure S32. Mass spectrum of compound 3h

RT: 0.47 - 2.84 SM: 7B





F345-OCH3 #304 RT: 5.10 P: + SB: 2 3.73, 3.73 NL: 2.10E3
T: {0,0} + c EI Full ms [40.00-1000.00]



Supplementary Information

Fig. S33. IC₅₀ curves (for MCF-7, HepG2 and A594) of the compounds 2a-b & 3a-h



Supplementary Information

A549

